Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

Cell

Volumn 162, Issue 6, 2015, Pages 1229-1241

  Chang, Chih Hao ^a   Qiu, Jing ^a,c   O'Sullivan, David ^a,c   Buck, Michael D ^a,c   Noguchi, Takuro ^a   Curtis, Jonathan D ^a,c   Chen, Qiongyu ^a   Gindin, Mariel ^a   Gubin, Matthew M ^a   Van Der Windt, Gerritje J W ^a,b   Tonc, Elena ^a   Schreiber, Robert D ^a   Pearce, Edward J ^a   Pearce, Erika L ^a,c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c MAX PLANCK INSTITUTE OF IMMUNOBIOLOGY AND EPIGENETICS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GLUCOSE; GLUCOSE TRANSPORTER 1; GLYCOLYTIC ENZYME; HEXOKINASE 2; MYC PROTEIN; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PHOSPHOTRANSFERASE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; UNCLASSIFIED DRUG; CD274 PROTEIN, MOUSE; GAMMA INTERFERON; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER GROWTH; CELL INFILTRATION; CELL METABOLISM; CONTROLLED STUDY; CYTOKINE PRODUCTION; GLUCOSE COMPETITION; GLUCOSE INTAKE; GLUCOSE METABOLISM; GLUCOSE TRANSPORT; GLUCOSE UTILIZATION; GLYCOLYSIS; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR REJECTION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CD8+ T LYMPHOCYTE; IMMUNOLOGY; METABOLISM; NEOPLASM; TUMOR ASSOCIATED LEUKOCYTE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; CTLA-4 ANTIGEN; GLYCOLYSIS; INTERFERON-GAMMA; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84941344937     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2015.08.016     Document Type: Article

References (61)

1. M. Ahmadzadeh, L.A. Johnson, B. Heemskerk, J.R. Wunderlich, M.E. Dudley, D.E. White, and S.A. Rosenberg Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired Blood 114 2009 1537 1544
2. A. Anichini, A. Molla, C. Vegetti, I. Bersani, R. Zappasodi, F. Arienti, F. Ravagnani, A. Maurichi, R. Patuzzo, M. Santinami, and et al. Tumor-reactive CD8+ early effector T cells identified at tumor site in primary and metastatic melanoma Cancer Res. 70 2010 8378 8387
3. + T cells in metastases from melanoma patients J. Clin. Invest. 121 2011 2350 2360
4. A.S. Berghoff, B. Kiesel, G. Widhalm, O. Rajky, G. Ricken, A. Wohrer, K. Dieckmann, M. Filipits, A. Brandstetter, M. Weller, and et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma Neuro-oncol. 17 2014 1064 1075
5. K. Birsoy, R. Possemato, F.K. Lorbeer, E.C. Bayraktar, P. Thiru, B. Yucel, T. Wang, W.W. Chen, C.B. Clish, and D.M. Sabatini Metabolic determinants of cancer cell sensitivity to glucose limitation and biguanides Nature 508 2014 108 112
6. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N. Engl. J. Med. 366 2012 2455 2465
7. R. Carlsson, and S. Issazadeh-Navikas PD-L1, Inflammation and Glioblastoma J Immunol Clin Res 2 2014 1013
8. C.M. Cham, G. Driessens, J.P. O'Keefe, and T.F. Gajewski Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells Eur. J. Immunol. 38 2008 2438 2450
9. C.H. Chang, J.D. Curtis, L.B. Maggi Jr., B. Faubert, A.V. Villarino, D. O'Sullivan, S.C. Huang, G.J. van der Windt, J. Blagih, J. Qiu, and et al. Posttranscriptional control of T cell effector function by aerobic glycolysis Cell 153 2013 1239 1251
10. S. Constant, C. Pfeiffer, A. Woodard, T. Pasqualini, and K. Bottomly Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells J. Exp. Med. 182 1995 1591 1596
11. J. Crespo, H. Sun, T.H. Welling, Z. Tian, and W. Zou T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment Curr. Opin. Immunol. 25 2013 214 221
12. H. Dong, S.E. Strome, D.R. Salomao, H. Tamura, F. Hirano, D.B. Flies, P.C. Roche, J. Lu, G. Zhu, K. Tamada, and et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion Nat. Med. 8 2002 793 800
13. C.A. Doughty, B.F. Bleiman, D.J. Wagner, F.J. Dufort, J.M. Mataraza, M.F. Roberts, and T.C. Chiles Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth Blood 107 2006 4458 4465
14. E. Favaro, K. Bensaad, M.G. Chong, D.A. Tennant, D.J. Ferguson, C. Snell, G. Steers, H. Turley, J.L. Li, U.L. Günther, and et al. Glucose utilization via glycogen phosphorylase sustains proliferation and prevents premature senescence in cancer cells Cell Metab. 16 2012 751 764
15. K. Fischer, P. Hoffmann, S. Voelkl, N. Meidenbauer, J. Ammer, M. Edinger, E. Gottfried, S. Schwarz, G. Rothe, S. Hoves, and et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells Blood 109 2007 3812 3819
16. L.M. Francisco, P.T. Sage, and A.H. Sharpe The PD-1 pathway in tolerance and autoimmunity Immunol. Rev. 236 2010 219 242
17. K.A. Frauwirth, J.L. Riley, M.H. Harris, R.V. Parry, J.C. Rathmell, D.R. Plas, R.L. Elstrom, C.H. June, and C.B. Thompson The CD28 signaling pathway regulates glucose metabolism Immunity 16 2002 769 777
18. R.A. Gatenby, and R.J. Gillies Why do cancers have high aerobic glycolysis? Nat. Rev. Cancer 4 2004 891 899
19. V.A. Gerriets, R.J. Kishton, A.G. Nichols, A.N. Macintyre, M. Inoue, O. Ilkayeva, P.S. Winter, X. Liu, B. Priyadharshini, M.E. Slawinska, and et al. Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation J. Clin. Invest. 125 2015 194 207
20. J.D. Gordan, C.B. Thompson, and M.C. Simon HIF and c-Myc: sibling rivals for control of cancer cell metabolism and proliferation Cancer Cell 12 2007 108 113
21. M.M. Gubin, X. Zhang, H. Schuster, E. Caron, J.P. Ward, T. Noguchi, Y. Ivanova, J. Hundal, C.D. Arthur, W.J. Krebber, and et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens Nature 515 2014 577 581
22. O. Hamid, C. Robert, A. Daud, F.S. Hodi, W.J. Hwu, R. Kefford, J.D. Wolchok, P. Hersey, R.W. Joseph, J.S. Weber, and et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma N. Engl. J. Med. 369 2013 134 144
23. M.E. Hatten, and M.L. Shelanski Mouse cerebellar granule neurons arrest the proliferation of human and rodent astrocytoma cells in vitro J. Neurosci. 8 1988 1447 1453
24. F.S. Hodi, S.J. O'Day, D.F. McDermott, R.W. Weber, J.A. Sosman, J.B. Haanen, R. Gonzalez, C. Robert, D. Schadendorf, J.C. Hassel, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N. Engl. J. Med. 363 2010 711 723
25. S.C. Huang, B. Everts, Y. Ivanova, D. O'Sullivan, M. Nascimento, A.M. Smith, W. Beatty, L. Love-Gregory, W.Y. Lam, C.M. O'Neill, and et al. Cell-intrinsic lysosomal lipolysis is essential for alternative activation of macrophages Nat. Immunol. 15 2014 846 855
26. S. Issazadeh-Navikas Alerting the immune system via stromal cells is central to the prevention of tumor growth OncoImmunology 2 2013 e27091
27. S.R. Jacobs, C.E. Herman, N.J. Maciver, J.A. Wofford, H.L. Wieman, J.J. Hammen, and J.C. Rathmell Glucose uptake is limiting in T cell activation and requires CD28-mediated Akt-dependent and independent pathways J. Immunol. 180 2008 4476 4486
28. M.E. Keir, M.J. Butte, G.J. Freeman, and A.H. Sharpe PD-1 and its ligands in tolerance and immunity Annu. Rev. Immunol. 26 2008 677 704
29. D.H. Kim, D.D. Sarbassov, S.M. Ali, J.E. King, R.R. Latek, H. Erdjument-Bromage, P. Tempst, and D.M. Sabatini mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery Cell 110 2002 163 175
30. K. Kingwell Neuro-oncology: Glioblastoma prognosis linked to neuronal PD-L1 expression in tumour-adjacent tissue Nat. Rev. Neurol. 9 2013 602 603
31. A.D. Kohn, A. Barthel, K.S. Kovacina, A. Boge, B. Wallach, S.A. Summers, M.J. Birnbaum, P.H. Scott, J.C. Lawrence Jr., and R.A. Roth Construction and characterization of a conditionally active version of the serine/threonine kinase Akt J. Biol. Chem. 273 1998 11937 11943
32. A. Lanzavecchia, and F. Sallusto Progressive differentiation and selection of the fittest in the immune response Nat. Rev. Immunol. 2 2002 982 987
33. M. Laplante, and D.M. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
34. Y. Liu, R. Carlsson, M. Ambjørn, M. Hasan, W. Badn, A. Darabi, P. Siesjö, and S. Issazadeh-Navikas PD-L1 expression by neurons nearby tumors indicates better prognosis in glioblastoma patients J. Neurosci. 33 2013 14231 14245
35. H. Matsushita, M.D. Vesely, D.C. Koboldt, C.G. Rickert, R. Uppaluri, V.J. Magrini, C.D. Arthur, J.M. White, Y.S. Chen, L.K. Shea, and et al. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting Nature 482 2012 400 404
36. A.L. Mellor, and D.H. Munn Creating immune privilege: active local suppression that benefits friends, but protects foes Nat. Rev. Immunol. 8 2008 74 80
37. R.D. Michalek, V.A. Gerriets, S.R. Jacobs, A.N. Macintyre, N.J. MacIver, E.F. Mason, S.A. Sullivan, A.G. Nichols, and J.C. Rathmell Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets J. Immunol. 186 2011 3299 3303
38. M.B. Mockler, M.J. Conroy, and J. Lysaght Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment Front. Oncol. 4 2014 107
39. D.H. Munn, and A.L. Mellor Indoleamine 2,3 dioxygenase and metabolic control of immune responses Trends Immunol. 34 2013 137 143
40. D.H. Munn, E. Shafizadeh, J.T. Attwood, I. Bondarev, A. Pashine, and A.L. Mellor Inhibition of T cell proliferation by macrophage tryptophan catabolism J. Exp. Med. 189 1999 1363 1372
41. D.G. Nicholls, V.M. Darley-Usmar, M. Wu, P.B. Jensen, G.W. Rogers, and D.A. Ferrick Bioenergetic profile experiment using C2C12 myoblast cells J. Vis. Exp. 46 2010 2511
42. D. O'Sullivan, and E.L. Pearce Targeting T cell metabolism for therapy Trends Immunol. 36 2015 71 80
43. D.B. Page, M.A. Postow, M.K. Callahan, J.P. Allison, and J.D. Wolchok Immune modulation in cancer with antibodies Annu. Rev. Med. 65 2014 185 202
44. I.A. Parish, and S.M. Kaech Diversity in CD8(+) T cell differentiation Curr. Opin. Immunol. 21 2009 291 297
45. R.V. Parry, J.M. Chemnitz, K.A. Frauwirth, A.R. Lanfranco, I. Braunstein, S.V. Kobayashi, P.S. Linsley, C.B. Thompson, and J.L. Riley CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms Mol. Cell. Biol. 25 2005 9543 9553
46. N. Patsoukis, K. Bardhan, P. Chatterjee, D. Sari, B. Liu, L.N. Bell, E.D. Karoly, G.J. Freeman, V. Petkova, P. Seth, and et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation Nat. Commun. 6 2015 6692
47. E.L. Pearce, M.C. Poffenberger, C.H. Chang, and R.G. Jones Fueling immunity: insights into metabolism and lymphocyte function Science 342 2013 1242454
48. V.A. Pedicord, J.R. Cross, W. Montalvo-Ortiz, M.L. Miller, and J.P. Allison Friends not foes: CTLA-4 blockade and mTOR inhibition cooperate during CD8+ T cell priming to promote memory formation and metabolic readiness J. Immunol. 194 2015 2089 2098
49. S.A. Quezada, and K.S. Peggs Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer Br. J. Cancer 108 2013 1560 1565
50. R.R. Rao, Q. Li, and P.A. Shrikant Fine-tuning CD8(+) T cell functional responses: mTOR acts as a rheostat for regulating CD8(+) T cell proliferation, survival and differentiation? Cell Cycle 9 2010 2996 3001
51. T.R. Simpson, F. Li, W. Montalvo-Ortiz, M.A. Sepulveda, K. Bergerhoff, F. Arce, C. Roddie, J.Y. Henry, H. Yagita, J.D. Wolchok, and et al. Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J. Exp. Med. 210 2013 1695 1710
52. S. Spranger, H.K. Koblish, B. Horton, P.A. Scherle, R. Newton, and T.F. Gajewski Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment J. Immunother. Cancer 2 2014 3
53. M.K. Srivastava, P. Sinha, V.K. Clements, P. Rodriguez, and S. Ostrand-Rosenberg Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine Cancer Res. 70 2010 68 77
54. M.M. Staron, S.M. Gray, H.D. Marshall, I.A. Parish, J.H. Chen, C.J. Perry, G. Cui, M.O. Li, and S.M. Kaech The transcription factor FoxO1 sustains expression of the inhibitory receptor PD-1 and survival of antiviral CD8(+) T cells during chronic infection Immunity 41 2014 802 814
55. D. Vats, L. Mukundan, J.I. Odegaard, L. Zhang, K.L. Smith, C.R. Morel, R.A. Wagner, D.R. Greaves, P.J. Murray, and A. Chawla Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation Cell Metab. 4 2006 13 24
56. M.D. Vesely, and R.D. Schreiber Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy Ann. N Y Acad. Sci. 1284 2013 1 5
57. R. Wang, C.P. Dillon, L.Z. Shi, S. Milasta, R. Carter, D. Finkelstein, L.L. McCormick, P. Fitzgerald, H. Chi, J. Munger, and D.R. Green The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation Immunity 35 2011 871 882
58. O. Warburg On the origin of cancer cells Science 123 1956 309 314
59. E.E. West, H.T. Jin, A.U. Rasheed, P. Penaloza-Macmaster, S.J. Ha, W.G. Tan, B. Youngblood, G.J. Freeman, K.A. Smith, and R. Ahmed PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells J. Clin. Invest. 123 2013 2604 2615
60. E.J. Wherry T cell exhaustion Nat. Immunol. 12 2011 492 499
61. J.D. Wolchok, H. Kluger, M.K. Callahan, M.A. Postow, N.A. Rizvi, A.M. Lesokhin, N.H. Segal, C.E. Ariyan, R.A. Gordon, K. Reed, and et al. Nivolumab plus ipilimumab in advanced melanoma N. Engl. J. Med. 369 2013 122 133